

Daftar Pustaka

- Aldemir, M., Okulu, E., Kosemehmetoglu, K., Ener, K., Topal, F., Evirgen, O., Gurleyik, E., & Avci, A. (2013). Evaluation of the protective effect of quercetin against cisplatin-induced renal and testis tissue damage and sperm parameters in rats. *Andrologia*, 1, 1-9.
- Anjaneyulu, M., & Chopra, K. (2014). Quercetin, an anti-oxidant bioflavonoid, attenuates diabetic nephropathy in rats. *Clin Exp Pharmacol Physiol*, 31(4), 244–248.
- Becker, G.J., & Hewitson, T.D. (2013). Animal models of chronic kidney disease : useful but not perfect. *Nephrol Dial Transplant*, 28, 2432-2438.
- Bhattacharjee, N., Barma, S., Konwar, N., Dewanjee, S., & Manna, P. (2016). Mechanistic insight of diabetic nephropathy and its pharmacotherapeutic targets : an update. *European Journal of Pharmacology*, 791, 8-24.
- Campbell, K.N., Raij, L., & Mundel, P. (2011). Role of angiotensin II in the development of nephropathy and podocytopathy of diabetes. *Curr Diabetes Rev*, 7(1), 3-7.
- Coqueiro, A., Regasini, L.O., Regasini, S.C., Queiroz, M.M., Silva, D.H., daSilva & Bolzani V. (2013). Free radical scavenging activity of Kielmeyera variabilis Clusiaceae. *Molecules*, 18(2), 2376–2385.
- Dharma, Surya. (2016). *Patofisiologi, Farmakologi, Farmakoterapi*. Yogyakarta : GRE Publishing.
- Dipiro, J. T., Talbert, L. R., Yee, G. C., Matzke, G. R., Wells, A. G., & Posey, L. M. (2008). *Pharmacotherapy, A Pathophysiologic Approach*. New York : Mc Graw Hill Medical.
- El-Mahdy, N. A., El-Sayad, M., & El-Kadem, A. H. (2016). Combination of telmisartan with sildenafil ameliorate progression of diabetic nephropathy in streptozotocin-induced diabetic model. *Biomedicine & Pharmacotherapy*, 81, 136–144.
- Elmas, O., Erbasb, O., & Yigitturk, G. (2016). The efficacy of Aesculus hippocastanum seeds on diabetic nephropathy in a streptozotocin-induced diabetic rat model. *Biomedicine & Pharmacotherapy*, 83, 392–396.
- Eroschenko, Victor P. (2012). *Atlas Histologi diFiore*. Jakarta : EGC.

- Ganong, William F. (1998). *Review of Medical Physiology*. Jakarta : EGC.
- Guyton, Arthur C. & Hall, John E. (1997). *Textbook of Medical Physiology*. Jakarta : EGC.
- Gomes, I., Porto, M., Santos, M.C., Campagnaro, B., Pereira, T., Meyrelles, S., & Vasquez, E. (2014). Renoprotective, anti-oxidative and anti-apoptotic effects of oral low-dose quercetin in the C57BL/6J model of diabetic nephropathy. *Lipids in Health and Disease*, 13, 184.
- Goud, B.J., Dwarakanath, V., Chikka, B.K. (2015). Streptozocin - a diabetogenic agent in animal models. *International Journal of Pharmacy & Pharmaceutical Research*. 3(1), 253-269.
- Hammersen, S. (1996). *Histologi* (Edisi IV). Alih Bahasa : T. Harjanto. Jakarta : EGC.
- Harper, H.A., Radwell, V.W., & Mayers, P.A. (1979). *Review of Physiological Chemistry* (17th ed). California : Lange Medical Publication.
- Jayasekara, T.I., Stevenson, P.C., Belmain, S.R., Farman, D.I., & Hall, D.R. (2002). Identification of methylsalicylate as the principal volatile component in the methanol extract of root bark of *Securidaca longipedunculata* Fers. *J. Mass Spec.* 37, 577-580.
- Jankun, J. (2012). Challenging delivery of VLHLN plasminogen activator inhibitor - 1 by osmotic pumps in diabetic mouse : a case report. *Exp.Ther.Med.* 4, 661-664.
- Janqueira, L. C. J., & Kelly. (1998). *Histologi Dasar* (Edisi III). Penerjemah : J. Tambayong. Jakarta : EGC.
- Jusuf, A. A. (2009). *Histoteknik Dasar*. Jakarta : Fakultas Kedokteran Universitas Indonesia.
- Kelly, G. S. (2011). Quercetin. *Alternative Medicine Review*, 16(2), 172-194.
- Leeson, C.R., Leeson T.S., & Paparo, A.A. (2012). *Textbook of Histology*. Penerjemah : J. Tambayong. Jakarta : EGC.
- Lucida, H., Febriyenti, Pradana, R., & Rahmatika, L. (2016). Preparation of quercetin nanocrystals by planetary ball mill to increase the solubility and the dissolution profile. *Der Pharmacia Lettre*. 8(18) : 53-58.
- Majalah Tempo, edisi 15-21 Februari 2016.

- Miller, G., Myers, G.L., Ashwood, E.R., Killeen, A.A., Wang, E., & Thienpont, L.M. (2005) . Creatinine measurement. *Arch Pathol Lab Med*, 129, 297-304.
- Morikawa, K., Nonaka, M., Narahara, M, Torii, I., Kawaguchi, K., Yoshikawa, T., Kumazawa, Y., & Morikawa, S. (2003) . Inhibitory effect of quercetin on carrageenan-induced inflammation in rats . *Life Sci*, 26(6), 709-21.
- Moskuag, J.O., Carlson, H., & Myhrstad, M. (2004). Molecular imaging of the biological effects of quercetin and quercetin-rich foods. *Mechanism of Ageing and Development*, 125, 315-24.
- Murray, K. R., Barnner, D. K., Mayers, P. A., & Radwell, V. W. (1999). *Harper's Biochemistry*. Penerjemah Hartono. Jakarta : EGC.
- Ojima, A., Ishibashi, Y., Matsui, T., Maeda, S., Nishino, Y., Takeuchi, M., Fukami, K., & Yamagishi, S., (2013). Glucagon - like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltransferase-1 expression. *Am. J. Pathol.* 182,132–141.
- Packham, D.K., Alves, T.P., Dwyer, J.P., Atkins, R., deZeeuw, D., Cooper, M., Shahinfar, S., Lewis, J.B., & Lambers, H.J. (2012). Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy : results from the DIAMETRIC (diabetes mellitus treatment for renal insufficiency consortium) database. *Am. J. Kidney Dis.* 59,75–83.
- Parving, H.H. (2001). Diabetic nephropathy : prevention and treatment. *Kidney Int.* 60, 2041–2055.
- Pasternock, A., & Wilson, L. M. (1991). Creatinin urine. *Scond. J. Clin Lob. Invest*, 27, 1-7.
- Perez-Vizcaino F, Duarte J, Jimenez R, Santos-Buelga C, & Osuna A. (2009). Antihypertensive effects of the flavonoid quercetin. *Pharmacol Rep*, 61(1):67–75.
- Price, S.A., & Wilson, L.M. (1995). *Patofisiologi*. Jakarta : EGC.
- Ross, J.A, & Kasum, C.M. (2002) . Dietary flavonoids: bioavailability, metabolic effects, and safety. *Annu Rev Nutr* , 22, 19-34.

- Rossing, P., (2006). Diabetic nephropathy : worldwide epidemic and effects of current treatment on natural history. *Curr. Diab Rep.* 6,479–483.
- Sabir, A. (2003). *Pemanfaatan flavonoid di bidang kedokteran gigi*. Majalah kedokteran gigi. Edisi khusus temu ilmiah nasional III. Surabaya: FKG Unair.
- Sahoo, N. G., Kakran, M., Shaal, L. A., Li, L., Muller, R. H., Pal, M., & Tan, L.P., (2011). Preparation and characterization of quercetin nanocrystals. *Journal of Pharmaceutical Sciences*, 100(6) : 2379-2390.
- Sherwood, Lauralee. 2001. *Fisiologi manusia*. Jakarta : EGC.
- Shuvy, M., Nyska, A., Beerli, R., Abedat, S., Gal-Moscovici, A., & Rajamannan, N. M. (2011). Histopathology and apoptosis in an animal model of reversible renal injury. *Experimental Toxicology and Pathology*, 63, 303–306.
- Suntoro, S. H. (1983). *Metode pewarnaan*. Jakarta : Bharata Karya Aksara.
- Sweetman, Sean C. (2009). *Martindale, the complete drug reference*. London : Pharmaceutical Press.
- Toussaint, N. (2012) . *Screening for early chronic kidney disease* (pp. 30-35). The CARI guidelines. Australia: Saunder.
- Vivek, K.S. (2010). Streptozotocin : an experimental tool in diabetes and alzheimer's disease (A- Review). *Int J Pharma Res Dev*, 2(1), 1–7.
- Wahyuni, Putri. 2015. Karakterisasi dan Toksisitas Sub Akut Ekstrak Etanol Daun Benalu (*Scurrula ferruginea Jack Danser*) yang Tumbuh pada Pohon Kopi terhadap Aktivitas SGPT dan Kadar Kreatinin Serum Mencit Putih Jantan (Skripsi). Padang : Universitas Andalas.
- Weanen. (2002) . New marker for kidney disease. *Clinical Chemistry*, 3 , 1375-89.
- Wu, D., Peng, F., Zhang, B., Ingram, A.J., Kelly, D.J., Gilbert,R.E., Gao, B., & Krepinsky, J.C. (2009). PKC – beta 1 mediates glucose – induced Akt activation and TGF - beta1 upregulation in mesangial cells. *J. Am. Soc. Nephrol.* 20,554–566.